Considering the Side Effects of Drugmakers’ Money-Back Guarantees by KATIE THOMAS and CHARLES ORNSTEIN

By KATIE THOMAS and CHARLES ORNSTEIN

The Trump administration is considering encouraging lowering drug costs through outcome-based contracts, but there is little evidence the approach works.

Published: July 9, 2017 at 08:00PM

from NYT Health http://ift.tt/2u07daw
via IFTTT

from WordPress http://ift.tt/2tAOT6H
via IFTTT